糖尿病治疗的新希望.pptVIP

* Key challenges of type 2 diabetes * * Over time, glycaemic control deteriorates UKPDS clearly showed the need for new diabetes treatments In UKPDS, the yearly median HbA1c in patients receiving conventional treatment increased steadily throughout the trial. In contrast, median HbA1c fell during the first year in patients receiving intensive treatment (glibenclamide, metformin or insulin) but gradually increased subsequently and only remained within the recommended treatment target for the first 3–6 years of treatment (depending on assigned treatment). During the remaining years of follow-up,